Early trial tests new Drug's effect on damaged livers
NCT ID NCT00666016
Summary
This small, completed study tested whether a one-month course of an experimental drug called TRO19622 was safe and could improve liver health in people with NASH, a type of fatty liver disease. Twenty-two adults with confirmed NASH received either the drug or a placebo. The main goal was to see if the drug safely lowered key liver enzymes, which are markers of liver damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU AMIENS, Service d'Hépato-Gastroentérologie
Amiens, 80054, France
-
Centre Hospitalier de Hyères, Hôpital de Jour, Service d'Hépato-Gastro-Entérologie
Hyères, 83407, France
-
Groupe Hospitalier Pitié-Salpétrière - Sce Hépato-Gastroentérologie - 47-83 Bd de l'Hôpital
Paris, 75651, France
-
Hôpital Archet 2 - Pôle de Référence Hépatite C (Niveau -2) - 151, route Saint Antoine de Ginestière
Nice, 06200, France
-
Hôpital Saint Joseph, Service d'Hépato-Gastro-Entérologie
Marseille, 13285, France
Conditions
Explore the condition pages connected to this study.